- Historical clinical trial eligibility considerations in advanced NSCLC
- Clinical evidence from one of the largest advanced NSCLC trials conducted to date
- Resources to help support your eligible patients
| To view this email as a web page, click here. |
|
| Please join us to learn about a new FDA-approved first-line monotherapy option in advanced NSCLC |
| Wednesday, March 31 • 5:00 pm EST |
| Topics of discussion at this virtual event include: |
|
 |
|
| Expert insights provided by: | |
 |
|
|
Mark A. Socinski, MD Executive Medical Director Member, Thoracic Oncology Program AdventHealth Cancer Institute Orlando, FL |
|
| In accordance with the PhRMA Code on Interactions with Healthcare Professional, this Program is limited to U.S. Healthcare Professionals and persons with bona fide professional interest in the information presented. No CME credits offered for attendance of this program. | |
| Sponsored by | |
 |
|
| ONC.21.01.0015 2/21 | |
 |
|